Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy.

Zapata, Rodrigo; Sandoval, Lorena; Palma, José Luis; Hernández, Ismael; Ribalta, J; Reyes, Humberto; Sedano, M; Tohá, Dolores; Silva, Juan Jorge

doi:10.1111/j.1478-3231.2004.0996.x

Cited by 125 publications

(77 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…UDCA is hydrophilic bile acid. It is well tolerated by pregnant women, and no adverse effects in mothers or newborns have been observed [50,51,66] . Experimental evidence suggests that UDCA improves impaired hepatocellular secretion by mainly posttranscriptional stimulation of canalicular expression of transporters like the conjugate export pump, MRP2 (ABCC2), or the bile salt export pump, BSEP (ABCB11) [76,77] .…”

Section: Pharmacological Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Intrahepatic cholestasis of pregnancy-current achievements and unsolved problems

Kondrackienė¹,

Kupčinskas²

2008

WJG

View full text Add to dashboard Cite

Intrahepatic cholestasis of pregnancy (ICP) is the most common pregnancy-related liver disorder. Maternal effects of ICP are mild; however, there is a clear association between ICP and higher frequency of fetal distress, preterm delivery, and sudden intrauterine fetal death. The cause of ICP remains elusive, but there is evidence that mutations in genes encoding hepatobiliary transport proteins can predispose for the development of ICP. Recent data suggest that ursodeoxycholic acid is currently the most effective pharmacologic treatment, whereas obstetric management is still debated. Clinical trials are required to identify the most suitable monitoring modalities that can specifically predict poor perinatal outcome. This article aims to review current achievements and unsolved problems of ICP.

show abstract

Section: Pharmacological Treatmentmentioning

confidence: 99%

“…The rate of malformations or abortions is not increased in ICP. Recent data show a marked decrease in fetal complication rates possibly due to greater awareness of the disease, experienced management and treatment [50,51,66] . The mechanism for poor perinatal outcome remains unclear.…”

Section: Fetal Outcomementioning

confidence: 99%

Intrahepatic cholestasis of pregnancy-current achievements and unsolved problems

Kondrackienė¹,

Kupčinskas²

2008

WJG

View full text Add to dashboard Cite

show abstract

“…26 Pruritus and serum liver tests were measured weekly from the beginning of the study until their return to normality was documented postpartum. Decisions on whether deliveries should be induced or cesarean sections should be performed were taken by the attending obstetricians with total independence from our study.…”

Section: Methodsmentioning

confidence: 99%

Is a leaky gut involved in the pathogenesis of intrahepatic cholestasis of pregnancy?†‡§

et al. 2006

Self Cite

View full text Add to dashboard Cite

I ntrahepatic cholestasis of pregnancy (ICP) is a rare disorder of unknown cause that may develop during the third or second trimester of pregnancy and resolves rapidly after delivery. The chief complaint is pruritus, and serum liver tests reveal a mild cholestasis with increased levels of bile salts and aminotransferases. ICP may cause fetal distress, with stillbirths or premature deliveries leading to increased perinatal morbidity and mortality. 1,2 The pathogenesis of ICP appears to be multifactorial. Potential contributors include a genetic predisposition interacting with the effects of estrogen and progesterone metabolites on bile secretory mechanisms. 3 The influence of environmental factors has been suggested by the observation of a seasonal variability in the incidence of ICP, with highest rates reported during winter, a recurrence rate of only 45% to 70% in subsequent pregnancies of multiparous women, and the decrease in the prevalence of ICP detected in Sweden and Chile during recent decades. 4 Therefore, identifying factors that may explain these epidemiological changes appear to be important.The gastrointestinal mucosal epithelium is an essential barrier that normally restricts the passage of harmful molecules into the mucosa and systemic circulation. An increased intestinal permeability has been observed in patients with enteric damage, such as in inflammatory From the

show abstract

“…4,87,88 UDKA doğal hidrofilik bir ajandır. Hidrofobik olan safra asitlerinin detoksifikasyonunu sağlamakta ve safra kanallarını toksik safradan korumaktadır.…”

Section: ) Ursodeoksi̇koli̇k Asi̇tunclassified

Gestational Intrahepatic Cholestasis: Etiology, Maternal Outcome, Fetal Outcome and Management

Abide¹,

Vural²

2017

Turkiye Klinikleri J Health Sci

View full text Add to dashboard Cite

Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy.

Abstract: UDCA improved pruritus and biochemical cholestasis, and facilitated deliveries at term in ICP patients, with a higher birthweight compared with historical controls. The drug was well tolerated and no adverse effects were detected in their infants.

Cited by 125 publications

References 47 publications

Intrahepatic cholestasis of pregnancy-current achievements and unsolved problems

Intrahepatic cholestasis of pregnancy-current achievements and unsolved problems

Is a leaky gut involved in the pathogenesis of intrahepatic cholestasis of pregnancy?†‡§

Gestational Intrahepatic Cholestasis: Etiology, Maternal Outcome, Fetal Outcome and Management

Contact Info

Product

Resources

About